TriangleRevumenib (NCT06229912)
Revumenib trial for Leukemia (NCT06229912). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people aged at least 12, weighing at least 40 kilograms, with relapsed or refractory acute myeloid, lymphoid or mixed-lineage leukemia. Eligibility requires a specified genetic change linked to increased HOX activity.
The idea: revumenib blocks menin’s interaction with KMT2A, disrupting signals that support certain leukemia cells. Participants take it by mouth twice daily in 28-day cycles. Researchers assess responses, residual leukemia and safety; active uncontrolled brain or spinal leukemia is excluded.
This phase 2 study plans 40 patients. MD Anderson sponsors it; Houston and New York are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.